Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors

Sophie H Bots; Michelle M Schreuder; Jeanine E Roeters van Lennep; Sarah Watson; Eugène van Puijenbroek; N Charlotte Onland-Moret; Hester M den Ruijter

doi:10.1001/jamanetworkopen.2022.8224

Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors

JAMA Netw Open. 2022 Apr 1;5(4):e228224. doi: 10.1001/jamanetworkopen.2022.8224.

Authors

Sophie H Bots¹, Michelle M Schreuder², Jeanine E Roeters van Lennep², Sarah Watson³, Eugène van Puijenbroek^{4

5}, N Charlotte Onland-Moret⁶, Hester M den Ruijter¹

Affiliations

¹ Laboratory for Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
² Department of Internal Medicine, Vascular Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
³ Uppsala Monitoring Centre, Uppsala, Sweden.
⁴ Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.
⁵ Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen, the Netherlands.
⁶ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.

Abstract

This cross-sectional study investigates differences by sex in reporting of adverse drug reactions associated with angiotensin-converting enzyme inhibitors combining global and prescription-corrected databases.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin-Converting Enzyme Inhibitors* / adverse effects
Drug-Related Side Effects and Adverse Reactions*
Female
Humans
Male
Sex Characteristics

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors